A more complete understanding of the physiological and pathological role of lysophosphatidic acid (LPA) requires receptor subtype-specific agonists and antagonists. Here, we report the synthesis and pharmacological characterization of fatty alcohol phosphates (FAP) containing saturated hydrocarbon chains from 4 to 22 carbons in length. Selection of FAP as the lead structure was based on computational modeling as a minimal structure that satisfies the two-point pharmacophore developed earlier for the interaction of LPA with its receptors. Decyl and dodecyl FAPs (FAP-10 and FAP-12) were specific agonists of LPA 2 (EC 50 ϭ 3.7 Ϯ 0.2 M and 700 Ϯ 22 nM, respectively), yet selective antagonists of LPA 3 (K i ϭ 90 nM for FAP-12) and FAP-12 was a weak antagonist of LPA 1 . Neither LPA 1 nor LPA 3 receptors were activated by FAPs; in contrast, LPA 2 was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA 2 by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC 50 . The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA 3 -expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P 1,2,3,5 receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA 2 .
LPA 2 was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA 2 by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC 50 . The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA 3 -expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P 1,2,3,5 receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA 2 .
Lysophosphatidic acid (LPA) is a member of the phospholipid growth factor (PLGF) family. PLGFs exert pleiotropic biological effects, such as activating platelet aggregation and affecting cell proliferation, apoptosis, migration, and cell shape (for reviews, see Goetzl et al., 2000; Tigyi, 2001) . LPA elicits its biological effects through the activation of G protein-coupled receptors. In mammalian cells, three LPA-specific receptors have been identified, including LPA 1 (EDG-2), LPA 2 (EDG-4) and LPA 3 (EDG-7), all members of the endothelial differentiation gene (EDG) family (for review, see Contos et al., 2000) . In addition to LPA 1 , the PSP24 receptor was shown to elicit LPA-induced Ca 2ϩ -dependent Cl Ϫ -currents in Xenopus laevis oocytes (Guo et al., 1996; Fischer et al., 1998; Kimura et al., 2001) . Receptors LPA 1-3 share 50 to 54% sequence identity (Chun et al., 2002) . The EDG receptor family also contains five other receptors, S1P [1] [2] [3] [4] [5] , specific for the sphingolipid PLGF sphingosine 1-phosphate (S1P) (Chun et al., 2002) . The S1P receptors S1P 1-5 share 50% amino acid sequence identity and 35% identity with the LPA receptors (Chun et al., 2002) , suggesting possible similarities in the characteristics of ligand recognition in these receptors. Most cells express a combination of these receptors, making it difficult to dissect the biological effects mediated by an individual receptor subtype. The need to understand the biological function of PLGF receptors and the desire to pharmacologically exploit the differences in their ligand recognition requires the development of receptor subtype-specific agonists and antagonists. Until recently, no such compounds were available. Local and general anesthetics have been reported to inhibit PLGF receptors in X. laevis oocytes (Chan and Durieux, 1997; Tigyi et al., 1997) . Likewise, N-acyl serine phosphoric acid and N-acyl tyrosine phosphoric acid were shown to inhibit LPA-induced platelet aggregation, Cl Ϫ -currents in X. laevis oocytes, and neutrophil adhesion to vascular endothelial cells (Sugiura et al., 1994; Liliom et al., 1996a; Hooks et al., 1998; Siess et al., 1999) . However, in MDA MB231 cells, N-acyl serine phosphoric acid was shown to be a potent activator of LPA-like responses (Hooks et al., 1998) , although the receptor activated by this compound was not identified. This same compound was a weak agonist of LPA 1 and LPA 3 receptors heterologously expressed in Jurkat T cells . Cyclic phosphatidic acid was also shown to inhibit LPA-induced platelet aggregation (Gueguen et al., 1999) ; however, it is an LPA receptor agonist in X. laevis oocytes (Liliom et al., 1996b; Fischer et al., 1998) and in cells that heterologously express EDG family LPA receptors (Bandoh et al., 2000) .
Computational models for S1P 1 (Parrill et al., 2000) , LPA 1 , and LPA 2 Sardar et al., 2002) confirmed the importance of two specific interactions between each receptor and its phospholipid ligand. One of these interactions involves ion pairing between the phosphate group of LPA and two positively charged conserved residues in the third and seventh putative transmembrane segments of the LPA receptor subfamily. A second interaction involves hydrophobic residues within the transmembrane segment of the receptor and the hydrophobic tail of LPA (Fischer et al., 2001) . Based on these two points of interaction with the LPA pharmacophore, we identified dioctylglycerol pyrophosphate and dioctyl-phosphatidic acid as selective antagonists of LPA 1 and LPA 3 receptors, with an order of magnitude higher potency for LPA 3 (Fischer et al., 2001) . A stereoisomer of the 2-substituted N-acyl ethanolamide phosphate LPA analog containing a bulky benzyl-4-oxybenzyl group was shown to be a dual LPA 1 /LPA 3 competitive antagonist with higher inhibitory potency for LPA 1 (Heise et al., 2001 ).
Herein we report the synthesis and characterization of fatty alcohol phosphates (FAPs) that lack a glycerol backbone and therefore consist of only a polar phosphate head group and a hydrophobic tail and represent a minimal structure that satisfies the two-point pharmacophore introduced earlier for LPA-like structures (Fischer et al., 2001 , Sardar et al., 2002 . Pharmacological characterization of the ligand properties of FAPs showed an exquisite dependence on the length of the hydrocarbon chain. FAPs with 10, 12, and 14 carbons are agonists for LPA 2 and antagonists for the LPA 3 receptor. In contrast, other FAPs, with carbon chain lengths of 4, 8, 16, 18, and 22 , showed no agonist effect on any mammalian LPA receptor. FAP-14 and FAP-18 were weak antagonists of the LPA 3 receptor, along with FAP-10.
Materials and Methods

Materials
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL); other chemicals and fetal bovine serum were obtained from SigmaAldrich Chemical Co. (St. Louis, MO). Cell culture medium (Dulbecco's modified Eagle's medium) and G418 were purchased from Cellgro (Herndon, VA). Fura-2 acetoxymethyl ester was from Molecular Probes (Eugene, OR). Oocyte positive X. laevis frogs were from Xenopus I (Dexter, MI). Collagenase A was purchased from Roche Molecular Biochemicals (Mannheim, Germany). [
35 S]GTP-␥-S was purchased from Amersham Biosciences (Uppsala, Sweden). FLAG epitope-tagged cDNAs encoding human LPA 2 and LPA 3 receptors in pCDNA3 plasmids (Invitrogen, Carlsbad, CA) were a gift from Dr. Junken Aoki (University of Tokyo, Tokyo, Japan). S1P 1 cDNA was a gift from Dr. Timothy Hla (University of Connecticut, Storres, CT). PCDNA3.1 expression vector containing S1P 5 cDNA was a gift from Dr. Kevin Lynch (University of Virginia, Charlottesville, VA).
Chemical Synthesis of the FAP Compounds
All reagents and chromatography media were purchased from Sigma-Aldrich Chemical Co. or Fisher Scientific (Pittsburgh, PA) and were used without further purification. Thin-layer chromatography was performed on 200-m alumina plates (Silica gel 60 Å; E.M. Science, Hawthorne, NY). Flash chromatography was performed on silica gel (60 Å, 200 -425 mesh) . Melting points were determined on a Thomas-Hoover capillary melting point apparatus and are uncorrected.
1 H, 13 C, and 31 P nuclear magnetic resonance spectra were obtained on an AX 300 spectrometer (Bruker, Billerica, MA). Chemical shifts for 1 H and 13 C are reported as parts per million relative to tetramethylsilane. Spectra for 31 P are reported as parts per million relative to 0.0485 M triphenylphosphate in CDCl 3 . Electrospray ionization liquid chromatography/mass spectrometry was performed on a Bruker Esquire LC/MS system.
Synthesis of Phosphoric Acid Dibenzyl Ester Alkyl Esters (1-8a)
The synthesis of protected alkyl monophosphates (Fig. 1) was performed according to the method of Bittman et al. (1996) except that peracetic acid was used for the oxidation step instead of mchloroperoxybenzoic acid. Each anhydrous alcohol (1.0 mmol) and 365 mg (5.17 mmol) of 1H-tetrazole were dissolved in 34 ml of anhydrous methylene chloride. A solution of 0.895 g (2.58 mmol) of dibenzyl-N,N-diisopropyl phosphoramidite in 5 ml of anhydrous methylene chloride was added under an argon atmosphere. The reaction mixture was stirred at room temperature for 2 h and was then cooled to Ϫ38°C in an isopropyl alcohol/dry ice bath. Peracetic acid [0.815 g (3.43 mmol) of 32% acid] in 28 ml of anhydrous methylene chloride was added drop-wise, and the temperature of the reaction mixture was raised to 0°C and stirred for 1 h. To the reaction mixture, 200 ml of methylene chloride was added, and the organic layer was washed with 10% sodium metabisulfite (2 ϫ 40 ml), saturated sodium bicarbonate (2 ϫ 40 ml), water (30 ml), and brine (40 ml). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under vacuum to dryness. The resulting crude products were purified by silica gel chromatography using hexane/ethyl acetate (1:1 for 1a and 7:3 for 2-8a) to elute the desired product. 13 C NMR (CDCl 3 ) ␦ 14. 13, 22.69, 25.38, 29.12, 29.35, 29.49, 29.56, 29.63, 30.18 12, 22.70, 25.40, 29.13, 29.38, 29.51, 29.58, 29.68, 29.72, 30 .20 (d, J C,P ϭ 6.9 Hz), 31.94, 68.06 (d, J C,P ϭ 6.1 Hz), 69.14 (d, J C,P ϭ 5.4 Hz), 127.90, 128.47, 128.55, 136 .00 (d, J C,P ϭ 6.8 Hz .18(d, J C,P ϭ 6.9 Hz), 31.93, 68.06 (d, J C,P ϭ 6.0 Hz), 69.13 (d, J C,P ϭ 5.6 Hz), 127.89, 128.47, 128.55, 135.98 (d, J C,P 
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Synthesis of Phosphoric Acid Mono Alkyl Esters (1-8b)
200 mg of 1-8a was dissolved in 30 ml of anhydrous methanol in a pressure vessel (Fig. 1) . The vessel was purged with argon and ϳ200 mg of 10% Pd/C catalyst was added. The vessel was connected to a hydrogenation apparatus and a hydrogen atmosphere of ϳ 50 psi was maintained inside the reaction vessel at room temperature for 8 h. The reaction mixture was then filtered by vacuum through a pad of methanol-washed celite. Solvent was evaporated under vacuum, yielding the desired product. 21, 22.98, 25.84, 29.57, 29.67, 29.89, 29.92, 29.96, 29.98, 30.69 (d, J C,P 26, 23.14, 26.01, 29.74, 29.84, 30.06, 30.09, 30.16, 30.87 (d, J C,P 
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Molecular Modeling of the LPA 2 Receptor
The inactive and active models of LPA 2 were previously developed in our research group (Sardar et al., 2002) . Briefly, the inactive model of LPA 2 was developed by homology modeling using the MOE (molecular operating environment) program (version 2002:01; Chemical Computing Group, Montreal, ON, Canada) and was based on the bovine rhodopsin crystal structure (Palczewski et al., 2000) . The active model of the LPA 2 receptor was developed via homology modeling using MOE and was based on the validated model of S1P 1 (Parrill et al., 2000) . Autodock 3.0 (Morris et al., 1996 (Morris et al., , 1998 ) was used to calculate the docked energies for FAP-12 with both the inactive and active model of LPA 2 . Automated docking using the Lamarckian genetic algorithm (Morris et al., 1998) was applied to generate 100 complexes of FAP with the LPA 2 receptor (inactive and active forms) and LPA with the LPA 2 receptor (active form), to evaluate the binding region of the ligand. The best complex for each receptor, in terms of energy and binding position of the ligand, was energy minimized with the MMFF94 force field (Halgren, 1996) to a root-mean-square gradient of 0.01 kcal/mol/Å to allow the receptor to adapt to the presence of the ligand. The ligands were then removed from the minimized receptor-ligand complexes and 100 additional complexes were generated with Autodock to re-examine the binding energy after allowing the receptor to acclimatize to the ligand. Autodock 3.0 allows full flexibility of ligand torsion angles but does not provide opportunity for protein side chains to adapt to the presence of a ligand. Thus, the best protein-ligand complex found in an initial docking run was geometry optimized to allow protein side chains to optimize in the presence of the ligand. The ligand was then removed and docked back into the protein to obtain a final docked energy that better reflects the induced fit that occurs when proteinligand binding occurs. If a conformation similar to the one before minimization was not obtained, the docking run was repeated. When the preminimized conformation was located, the complex with the lowest docked energy was chosen as the best complex.
Cells and Cell Culture
Oocytes were harvested and treated as described earlier . RH7777 cells, stably expressing human LPA 2 receptors, were provided by Dr. Kevin Lynch (University of Virginia, Charlottesville, VA). All cell lines were maintained in Dulbecco's modified Eagle's medium, containing 10% fetal bovine serum and 2 mM glutamine, containing 250 g/ml G418 for the stable transfectants. RH7777 cells stably expressing LPA 1 and LPA 3 receptors have been generated by our group and characterized elsewhere (Fischer et al., 2001 ). N1E-115 and IEC-6 cells were purchased from American Type Culture Collection (Manassas, VA).
Cellular Assays
Electrophysiological recording from X. laevis oocytes was done using the standard two-electrode voltage clamp technique . Monitoring of intracellular Ca 2ϩ changes using Fura-2 acetoxymethyl ester fluorescent indicator and ligand-induced [
35 S]GTP-␥-S binding assays (Parrill et al., 2000) was performed as described in our previous publications. FAP samples were prepared fresh from methanolic stock solutions by diluting them in perfusion buffer directly before application. LPA samples were prepared the same way from a bovine serum albumin-complexed stock solution.
Lipid Phosphate Phosphatase Assay
Lipid phosphate phosphatase (LPP) activity was measured as described previously . Competitive inhibition of FAP-12 on LPP activity was analyzed according to the surface dilution kinetics model (Carman et al., 1995; Dillon et al., 1997) . A 100,000g pellet from mouse fibroblasts overexpressing mouse LPP1 was used as the enzyme source, and the reaction was performed in the presence of 2 mol% ([lipid] 
DNA Fragmentation Assay
The topoisomerase inhibitor camptothecin induces DNA fragmentation and apoptosis in rat IEC-6 intestinal epithelial cells that can be prevented by LPA (Deng et al., 2002) . To assess the agonist properties of FAP-12, IEC-6 cells were exposed to 20 M camptothecin for 6 h with or without FAP-12 (10 M) or LPA (10 M) pretreatment (15 min before camptothecin) and DNA fragmentation was measured using an enzyme-linked immunosorbent assay method with the cell death detection enzyme-linked immunosorbent assay kit from Roche (Indianapolis, IN). Briefly, cells were harvested and lysed in DNA lysis buffer for 30 min and centrifuged at 200 rpm for 10 min. An aliquot of the supernatant was incubated with antihistone-biotin plus anti-DNA peroxidase conjugated antibody in 96-well streptavidin-coated plates on a shaker for 2 h. After washing with the incubation buffer, 100 l of substrate buffer was added to each well and incubated for an additional 5 to 10 min. DNA absorbance was read at 405 nm in a microplate reader. Duplicates of the samples were used to quantify protein using the bicinchoninic acid assay kit from Pierce (Rockford, IL). DNA fragmentation was expressed as absorbance units per microgram of protein per minute.
RT-PCR Analysis of LPA Receptor Expression
To assess the expression of LPA receptor subtypes in N1E-115 cells, RT-PCR analysis was performed using a primer set and PCR protocol described in previous publications Fischer et al., 2001 ).
Data Analysis
The significance of differences between the groups was determined using the Student's t test. Values were considered significantly different at p Ͻ 0.05. The antagonists' binding constant, K i , was estimated by the method of Cheng (2002), as follows:
, where IC 50 is the half-effective concentration of the inhibitor, EC 50 is the half-effective concentration of the agonist (LPA), n H is the slope function (Hill-or cooperativity-exponent) in the logistic function that describes the agonist's activation curve, and [LPA] is the concentration of LPA against which the antagonist was being tested.
Results
The synthetic pathway used to generate FAPs is shown in Fig. 1 . Molecular structures were verified by NMR and mass spectrometry, and all spectral data were consistent with the assigned structures (see Materials and Methods).
FAPs with hydrocarbon chain lengths of 4, 8, 12, 18, and 22 were tested for their ability to enhance or inhibit LPA-induced Cl Ϫ currents in X. laevis oocytes. None of the FAP compounds activated Cl Ϫ currents in the oocytes when applied up to 10 M (data not shown). In contrast, all FAPs inhibited LPA-induced Cl Ϫ currents with varying potency. Dose-inhibition measurements revealed a strong correlation between chain length and inhibitory action (Fig. 2A) . The lowest IC 50 was observed using FAP-12 and FAP-8 (IC 50 ϭ 2.4 Ϯ 1 and 6 Ϯ 1 nM, respectively, against 5 nM oleoyl-LPA). FAPs with shorter or longer hydrocarbon chains than 12 were less effective in inhibiting the LPA responses.
When coapplied with LPA, FAP-12 shifted the LPA doseresponse curve to the right, suggesting a competitive mechanism for the antagonist activity (Fig. 2B) . In X. laevis oocytes the LPA dose-response curve has been shown to be biphasic and has been attributed to the presence of both high-and low-affinity binding sites (Guo et al., 1996; Liliom et al., 1996b) . When the LPA activation curve was measured in the presence of FAP-12, it could be fitted by a simple Langmuir isotherm, suggestive of only one binding site (Fig.  2B) . The activation curves measured in the absence and presence of the inhibitor run parallel at high LPA concentrations. Consequently, FAP-12 seems to inhibit only the highaffinity LPA binding site.
To characterize the effects of the FAP compounds in a mammalian system, we chose the RH7777 rat hepatoma cell line, which does not respond to LPA or S1P in a variety of cellular assays, including Ca 2ϩ mobilization, and does not express any of the known LPA and S1P receptors as monitored by RT-PCR (Zhang et al., 1999) . In cells stably expressing LPA 1 , FAP-12 weakly inhibited LPA-induced Ca 2ϩ -mobilization (Fig. 3) . In contrast, FAP-12 alone did not elicit intracellular Ca 2ϩ transients when applied up to 10 M (data not shown). Surprisingly, LPA 2 -expressing cells showed a dose-dependent increase in intracellular Ca 2ϩ mobilization in response to FAP-10 and FAP-12, with EC 50 values of 3.7 Ϯ 0.2 M and 700 Ϯ 22 nM, respectively (Fig. 4A ). FAP-14 was found to be a weak agonist, when applied at 10 M. In contrast, no other FAP analog elicited Ca 2ϩ mobilization, or inhibited the LPA response when applied in concentrations up to 10 M. The maximal response to FAP-12 was 50% of that elicited by LPA, suggesting that FAP-12 was a partial agonist of the LPA 2 receptor. When a concentration of 10 M was applied only FAP-10, FAP-12 and FAP-14 showed significant agonist activity (Fig. 4B ) with FAP-10 being the most efficacious.
Computational docking studies were used to evaluate the interactions of LPA and FAP with LPA 2 . When LPA (18:1) was docked against the active LPA 2 model, the lowest docked free energy was Ϫ15.08 kcal/mol. The binding pocket of LPA (18:1) was in the transmembrane domain with the phosphate group of LPA forming ion pairs with arginine 107 and lysine 278 (Fig. 5A ) and the 2-hydroxyl group of LPA hydrogen bonding with glutamine 108.
FAP-12 was docked against both the active and inactive models of LPA 2 . The lowest docked energy obtained upon evaluation of FAP-12 with the inactive form of LPA 2 was Ϫ9.98 kcal/mol. A more favorable docked energy, Ϫ12.44 kcal/mol, was obtained when FAP-12 was docked against the active form of LPA 2 , consistent with the agonist effect observed experimentally. The binding pocket of FAP-12 was located in the transmembrane domain and ion pairs were observed between the phosphate and two cationic residues, arginine 107 and lysine 278 of LPA 2 (Fig. 5B) . These interactions are consistent with our previous studies on the binding of LPA to the LPA receptors Sardar et al., 2002) .
Docking studies between FAP-8, FAP-10 (Fig. 5C ), FAP-14, and FAP-18 were performed using the active LPA 2 model, with resulting docked energies of Ϫ9.17, Ϫ10.46, Ϫ12.06, and Ϫ10.84 kcal/mol, respectively. The binding mode observed for these structures was similar to that observed for FAP-12. All four of these compounds had lower (less favorable) docked energies than FAP-12, as expected based on the experimental observation that FAP-12 had the lowest EC 50 . However, the relative energies did not correlate further with the experimentally observed receptor activation. Several factors probably contribute to this discrepancy. First, energies from docking studies are most reflective of binding affinity rather than molpharm.aspetjournals.org receptor activation. Second, binding is governed by the free energy change that occurs when a ligand moves from one environment (often aqueous solution) to another (a protein binding site). The docked energies represent only the enthalpic part of the free energy. The entropic part of the free energy, which consists of changes in conformational freedom and solvation effects, may be an important contributor to the differences in FAP compound activity.
RH7777 cells stably expressing the LPA 3 receptor did not respond to any of the FAPs by Ca 2ϩ mobilization when applied up to 10 M (data not shown). However, FAP-12 dose dependently inhibited LPA-induced Ca 2ϩ mobilization with a K i of 90 nM (Fig. 6A) . Coapplication of 300 nM FAP-12 with LPA shifted the dose-response curve of LPA to the right, increasing the EC 50 value from 300 Ϯ 14 to 1000 Ϯ 30 nM and suggesting a competitive type of inhibition (Fig. 6B ).
All FAPs were tested for their ability to inhibit LPA-elicited Ca 2ϩ -mobilization in cells expressing LPA 3 . Applied at a concentration of 200 nM, FAP-12 was the most effective (60% inhibition), followed by FAP-10, -14, and -18 (ϳ25% inhibition) (Fig. 6C) . FAP-4, -8, -16, and -22 did not inhibit the LPA response significantly at this concentration.
To determine whether the effects of FAPs were selective to LPA receptors, we examined the most potent analog, FAP-12, on responses elicited by various mammalian G-protein coupled receptors. In oocytes expressing poly(A) ϩ mRNA from rat brain, responses elicited by serotonin (10 M), kainate (100 M), and glutamate (10 M), which are mediated through the inositol trisphosphate-Ca 2ϩ pathway, were tested for interference by FAPs. In the presence of 10 M FAP-12, these responses relative to control were 103 Ϯ 8, 95 Ϯ 12, and 106 Ϯ 7% (n ϭ 3), respectively. The lack of inhibition indicates that FAP-12 did not inhibit these neurotransmitter receptors or the second-messenger systems mediating Ca 2ϩ -activated Cl Ϫ currents. Additionally, in RH7777 cells, FAP-12 (10 M) did not affect ATP-induced (1 M) Ca 2ϩ mobilization (101 Ϯ 10% of ATP alone control, n ϭ 3) indicating that in this mammalian cell line, just as in X. laevis oocytes, the compound did not interfere with ligandinduced Ca 2ϩ transients. The effects of FAP-12 were also tested on S1P receptors. GTP-␥-S loading assays were performed on RH7777 cells stably expressing S1P 1 . FAP-12, when coapplied with S1P (300 nM) up to 10 M, neither enhanced nor inhibited the substantial S1P-induced GTP loading. FAP-12 alone did not induce GTP loading in these cells (data not shown). Similar results were obtained with RH7777 cells transiently transfected with S1P5 (Table 1) . S1P elicits dose-dependent Ca 2ϩ transients in RH7777 cells expressing S1P 2 or S1P 3 . FAP-12 did not induce Ca 2ϩ mobilization in RH7777 cells transiently transfected with S1P 2 or S1P 3 , when applied in concentrations as high as 10 M, nor did it affect S1P-elicited Ca 2ϩ transients (Table 1) . We could not test FAP-12 on S1P 4 receptors, because, in our hands, this receptor did not respond to S1P in the GTP-␥-S loading or Ca 2ϩ -mobilization assays. To test whether FAP-12 interacts with LPP, a key enzyme of LPA degradation, enzymatic activity was measured in the absence or presence of FAP-12. LPP activity decreased to 73, 58, and 39% of control, when FAP-12 was added in 2-, 4-, and 8-fold excess, respectively (data not shown). This result suggests that FAP12 also interferes with the LPP-mediated degradative pathway of LPA.
To confirm the agonist properties of FAP-12 and FAP-10 on LPA 2 , these compounds were tested in N1E-115 neuroblastoma cells for Ca2ϩ mobilization effect (Fig. 7A ). N1E-115 cells express only LPA 2 receptor transcripts (Fig. 7B ) and respond to LPA with a transient elevation in [Ca 2ϩ ] i . FAP-12 and FAP-10 both elicited Ca 2ϩ transients in these neuroblastoma cells, confirming their agonist properties in a cell line that endogenously expresses only the LPA 2 receptor subtype. To further characterize the agonist properties of FAP-12 (Fig.  7C) , we examined its effect in an apoptosis protection assay using IEC-6 cells. These cells express predominantly LPA 2 along with lesser amounts of LPA 1 (Deng et al., 2002) . In these cells, FAP-12 applied at 10 M elicited a significant decrease in camptothecin-induced DNA fragmentation that was comparable with the effect of LPA (10 M). The results obtained from N1E-115 and IEC-6 cells lend strong support to the LPA-like agonist properties of FAPs in cell lines that express the LPA 2 receptor subtype.
Discussion
The phospholipid growth factors LPA and S1P are involved in numerous physiological and pathological processes, including regulation of cell proliferation and differentiation, apoptosis, Ca 2ϩ -homeostasis (Goetzl et al., 2000; Tigyi, 2001 ) and tumor cell invasion (Umezu-Goto et al., 2002) , and atherosclerosis (Siess et al., 1999) . Given that most cells express multiple PLGF receptor subtypes, the lack of subtype-specific agonists and antagonists for LPA receptors remains a limiting factor for the PLGF field. In an effort toward the rational design of such ligands, structural models of the PLGF receptors have been developed recently (Parrill et al., 2000; Wang et al., 2001; Sardar et al., 2002) . Based on computational modeling of the ligand-receptor interactions, we deduced and partially validated a model for receptor activation. The model assigned distinct functions to the polar headgroup and the hydrophobic tail within the LPA pharmacophore. In this model, the phosphate headgroup interacts with two positively charged conserved residues in the third and seventh transmembrane helices , whereas the hydrocarbon tail interacts with hydrophobic side-chains of amino acid residues lining the interhelical pocket (Sardar et al., 2002) . These hydrophobic interactions are predicted to be necessary for activation of the receptor (Fischer et al., 2001; Wang et al., 2001) . Specific recognition of S1P versus LPA is achieved through hydrogen bonding between the hydroxyl group of LPA and a glutamine or by ion pairing between the amino group of S1P and a glutamate in the third transmembrane helix conserved in the corresponding receptor subfamilies ). The two-point pharmacophore is consistent with the experimentally established structure-activity relationships of LPA (Lynch and Macdonald, 2002; Sardar et al., 2002) .
Our group (Fischer et al., 2001) and Dr. Lynch's group (Heise et al., 2001 ) have reported on LPA antagonists that show receptor subtype selectivity. A systematic screening of 2-OH-substituted N-acyl ethanolamide phosphates led to the discovery of a benzyl-4-oxybenzyl derivative of ethanolamine phosphate, of which the S-enantiomer exhibited selective antagonism of LPA 1 over LPA 3 , whereas it did not affect the LPA 2 receptor (Heise et al., 2001) . We found that dioctyl phosphatidic acid and dioctylglycerol pyrophosphate were weak antagonists of LPA 1 and strong antagonists for LPA 3 , whereas long-chain analogs (18:1) were not inhibitors of LPA receptors (Fischer et al., 2001) . It is important to note that short-chain LPA (8:0) was neither an agonist nor an antagonist in this system (Fischer et al., 2001 ). Both dioctylglycerol pyrophosphate and (S)-2-benzyl-4-oxybenzyl-N-acyl ethanolamide phosphate have a negatively charged phosphate head group. They also have two hydrocarbon side chains, unlike the physiological ligand, LPA. Therefore, both the length and size of the hydrophobic tail seems to affect the ability to activate or inhibit LPA receptors. Based on the two-point pharmacophore, we hypothesized that modifications within the hydrophobic tail of the ligand might have profound effects in determining agonist or antagonist behavior and therefore might allow identification of molecules with selective antagonistic properties.
Our earlier work (Bittman et al., 1996; , as well as of that of others (Hooks et al., 1998; Heise et al., 2001) , has shown that the glycerol backbone can be replaced by serine, tyrosine, or ethanolamine but maintain the LPA molpharm.aspetjournals.org mimetic effect of these lipid phosphate analogs. Fatty alcohol phosphates provide the simplest set of easy to synthesize analogs required to delineate the minimal structural requirement for a ligand using this hypothesis. For this reason we synthesized a series of FAP molecules with carbon chain lengths from 4 to 22 and characterized their effects on individual LPA and S1P receptor subtypes. Pharmacological analysis of the FAP series supports our hypothesis that the ionic headgroup attached to a hydrophobic tail are sufficient to make them ligands for all three LPA receptors, although with markedly different efficacies, potencies, and selectivities. FAP-10 and FAP-12 were specific agonists for LPA 2 with EC 50 values of 3.7 Ϯ 0.2 M and 700 Ϯ 22 nM, respectively, and specific antagonists for LPA 3 . FAP-12 also weakly inhibited LPA 1 . The decyl and dodecyl chain seem to be unique, which suggests that LPA 2 differs from the other two receptors in that it is activated by these relatively short-chain analogs. FAP molecules with carbon chain lengths shorter than 10 or longer than 14 did not affect LPA 2 and were weaker inhibitors of LPA 3 than FAP-12. Thus, the present results emphasize that acyl chain length plays a significant role in the ligand properties of LPA-like pharmacophores and establishes a distinguishing role in ligand recognition between the different LPA receptor subtypes. Furthermore, FAPs lack the glycerol backbone; thus, the present findings provide compelling evidence that it is not required for ligand activity. These observations are in complete agreement with earlier structure-activity studies in which LPA receptors showed a high degree of tolerance to analogs with serine, tyrosine, or ethanolamine in place of the glycerol backbone (Sugiura et al., 1994; Jalink et al., 1995; Lynch et al., 1997; Hooks et al., 1998) .
X. laevis oocytes express three pharmacologically distinguishable receptors for LPA (Liliom et al., 1996b; Fischer et al., 1998) . This heterogeneity is reflected in the dose-response curve, which is best described by assuming multiple sites with different high and low affinity for LPA (Guo et al., 1996; Liliom et al., 1996b) . Our experiments indicate that FAPs block only the high-affinity site (Fig. 2B) . Thus far, two high-affinity LPA sites have been identified in oocytes: the PSP24 (Guo et al., 1996) and LPA 1 receptors (Kimura et al., 2001) . Which of these is inhibited by FAPs remains unclear. The human ortholog of the LPA 1 receptor was only weakly inhibited by FAP-12 in concentrations in the high micromolar range (Fig. 3) . The highly conserved nature of mammalian and X. laevis LPA 1 tends to argue against the hypothesis that the inhibitor would target LPA1. On the other hand, overexpression of X. laevis LPA 1 in X. laevis oocytes augmented the endogenous LPA response (Kimura et al., 2001) , whereas the human ortholog did not . Interestingly, the chain length-dependence of the inhibitory potencies of FAPs in X. laevis oocytes ( Fig. 2A ) and in LPA 3 -expressing RH7777 cells (Fig. 6C) is very similar despite the consensus that oocytes do not express an LPA 3 receptor subtype (Kimura et al., 2001 ).
FAPs did not activate or inhibit S1P receptors, suggesting that this cluster within the EDG receptor family is fundamentally different from the LPA receptor cluster despite several similarities in ligand recognition. Based on earlier structure-activity measurements, a free amino group on the sphingoid backbone seems to be necessary for ligand recognition of the S1P receptors (Van Brocklyn et al., 1998) . This group is necessary for ligand binding (Parrill et al., 2000) and provides selectivity for these receptors to distinguish S1P from LPA . The absence of this free amino group in the FAP structure might explain the lack of effect of these molecules on S1P receptors. The agonist and antagonist effects of FAP-12 seem to be specific for LPA receptors because it did not modify the function of other heterologously expressed GPCRs in the X. laevis bioassay or RH7777 cells. The agonist properties of FAP-12 were confirmed in N1E-115 and IEC-6 cells that endogenously express LPA 2 receptor subtype (Fig. 7) . Thus, the present data identify FAP-12 as the first LPA 2 -selective agonist. Computational docking studies of , and LPA against the active form of LPA 2 suggest that the greatest affinity for all structures occurs in an overlapping region in the receptor. The energies observed for FAP-12 binding to the active and inactive models of the LPA 2 receptor, Ϫ12.44 kcal/mol versus Ϫ9.98 kcal/mol, are consistent with the experimental observation that FAP-12 is a partial agonist and thus interacts more strongly with the active conformation of the LPA 2 receptor. The lowest docked energy was observed for FAP-12 binding to the active model, a finding consistent with the observed lowest EC 50 value (700 Ϯ 22 nM) for this structure. Thus, the present results provide new refinements to our computational models.
FAP-12 inhibits LPA degradation by LPP, indicating that the simplified structure of the FAP molecule is also recognized by a key enzyme in the established degradation pathway of LPA. This observation suggests that FAP-12 will have at least three molecular targets: the LPA 3 and LPA 2 receptors and LPP enzymes.
The two-point pharmacophore for LPA receptor activation, which is based on our atomic resolution structural models of the PLGF receptors, makes the rational design of receptor subtype-selective agonists and antagonists possible, opening an important new avenue of research in the PLGF field. This approach identified FAPs as selective inhibitors of LPA 3 and the first subtype-specific agonists of LPA 2 receptors. Although the compounds identified here are not themselves likely to be useful clinically, they could serve as lead compounds for further development. Moreover, the differential effects of the acyl chain length derivatives of FAPs point to an important concept in designing subtype-selective reagents.
